Mr. Scott Cormack has more than two decades of experience in the biotechnology industry in executive management and venture capital. Scott has been President and CEO since August 2008, when OncoGenex Technologies Inc. completed a reverse takeover of Sonus Pharmaceuticals, Inc. to become OncoGenex Pharmaceuticals, Inc. Scott has led OncoGenex through significant corporate milestones, including private financings, leading the company from pre-clinical studies to completion of multiple Phase 2 clinical trials, initiation of Phase 3 trials and development of a robust pipeline. Scott was a co-founder of OncoGenex Technologies Inc., now a wholly owned subsidiary, where he served as President and a member of the Board of Directors since May 2000 and as Chief Executive Officer since February 2002. From 1998 to 2001, Scott served as Vice President of Milestone Medica Corporation, a seed venture capital firm investing in life sciences opportunities and joint venture between RBC Technology Ventures Inc. and Research Corporation Technologies. While at Milestone Medica, Scott served as interim President, Chief Executive Officer and Chairman of the Board of Directors of Salpep Biotechnology Inc., an asthma and inflammation biotechnology company, from 2000 to 2001. From 1995 to 1998, Scott served as Chief Operating Officer of NeuroSpheres Ltd, a neural stem cell biotechnology company. He was President and founder of For Tomorrow, a sole proprietorship engaged in business consulting, from 1991 to 1999. From 1986 to 1988, Scott served as Territory Manager of Vetrepharm Inc. (now Bioniche Life Sciences, Inc.), a biopharmaceutical company developing products for human and animal health markets, and from 1988 to 1991 he served as its Technology Manager, Immunomodulators. Scott holds a B.S. degree from the University of Alberta.
Dr. Jacobs is Executive Vice President and Chief Medical Officer at OncoGenex. She received her Ph.D. from Washington State University and her MD from the University of Washington Medical School. She has over twenty years of biotechnology experience in preclinical development, pharmacokinetic/drug metabolism studies, toxicology studies, Phase 1-4 clinical trials in a variety of therapeutic areas, regulatory affairs, biostatistics, data management, medical information and quality assurance.
Mr. John Bencich is an experienced financial executive who has spent nearly 15 years guiding financial strategy in the life sciences and technology industries. Prior to joining OncoGenex in 2014, John served as CFO of Integrated Diagnostics Inc. overseeing finance, corporate development, accounting and human resource functions. Before joining Integrated Diagnostics in 2012, John was CFO of Allozyne, a private, VC-backed company where he led the company's finance, accounting and information technology groups. Earlier he served as the vice president, CFO and treasurer of Trubion Pharmaceuticals, a publicly traded biotechnology company where he helped complete the successful sale of the company to Emergent BioSolutions. Prior to his role at Trubion, he was the director of finance and corporate controller for Onyx Software Corporation, a publicly traded software company. John started his career at Ernst & Young LLP. He graduated from the University of San Diego with a BA in Accounting, earned his MBA from Seattle University and is a Certified Public Accountant.
Kirsten Anderson joined OncoGenex in 2008 and was appointed Vice President, Clinical Operations in 2015. Kirsten has more than 20 years of experience in the pharmaceutical industry, with expertise in oncology drug development. Prior to joining OncoGenex, she held clinical trial management positions at Sonus Pharmaceuticals, Xcyte Therapies, and Immunex, including the oversight of global clinical operations, drug safety and data management. She has a laboratory research background and began her career at the University of Pennsylvania. Kirsten earned a degree in Biology from the University of Vermont.
Dr. Patricia Stewart serves as OncoGenex' Vice President of Clinical Development and previously as a Senior Medical Director. Prior to joining the company in 2005, she was a Senior Medical Director at Corixa Corporation. Patricia is Board Certified in Medical Oncology with 23 years of experience in teaching, clinical care and clinical research. She also served as a faculty member in Medical Oncology at the Fred Hutchinson Cancer Research Center and the University of Washington. She holds a B.A. degree from University of Buffalo, and an MA and MD from University of West Virginia.
Jaime Welch was appointed Vice President, Marketing and Corporate Communications in January 2012. Over the past decade, Jaime has held various sales and marketing positions with a specific concentration in Genitourinary Oncology. Prior to joining Oncogenex in July 2010, Jaime was the Global Marketing Director at Pfizer, Inc. responsible for in-line and pipeline strategic development of Sutent. She has also served in various Oncology Senior Marketing Management positions at Novartis Oncology and Abbott Laboratories. She began her pharmaceutical career as a Lupron Depot Sales Representative for TAP Pharmaceuticals in 2000. Jaime holds a degree in Communications from the University of Illinois.
- Corporate Governance
- Management & Board
- Stock Information
- SEC Filings
- Quarterly Results
- Analyst Coverage
- Webcasts & Presentations
- Scientific Publications & Presentations
- Frequently Asked Questions
© 2004-2017 OncoGenex Pharmaceuticals Inc. All rights reserved.
OncoGenex product candidates are investigational drugs for use only in approved clinical trials.
OncoGenex Pharmaceuticals is a drug discovery and development company uniquely focused on the challenge of cancer treatment resistance.
OncoGenex is uniquely focused on the challenge of cancer treatment resistance. We currently have several on-going clinical trials that may be of interest to you.
OncoGenex focuses on diverse molecular entities that target mechanisms of resistance and that have the potential to re-define treatment paradigms in a variety of cancers.
OncoGenex develops novel compounds designed to meet the persistent challenge of treatment resistance across a variety of cancers.